Last Price
20.16
Today's Change
+0.25 (1.25%)
Day's Change
19.70 - 20.72
Trading Volume
565,857
Market Cap
1 Billion
Shares Outstanding
57 Million
Avg Volume
909,395
Avg Price (50 Days)
20.09
Avg Price (200 Days)
15.59
PE Ratio
-6.57
EPS
-3.07
Earnings Announcement
08-Aug-2024
Previous Close
19.91
Open
20.37
Day's Range
19.7 - 20.7273
Year Range
7.64 - 30.189
Trading Volume
565,857
1 Day Change
1.26%
5 Day Change
9.68%
1 Month Change
17.96%
3 Month Change
-20.32%
6 Month Change
54.25%
Ytd Change
90.37%
1 Year Change
102.61%
3 Year Change
-18.51%
5 Year Change
-32.60%
10 Year Change
-32.60%
Max Change
-32.60%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.